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1. Introduction 
Osteoarthritis is a very common disease, and its prevalence increases with age. According to 
the American College of Rheumatology, nearly 70 % of people over age 70 have X – ray 
evidence of osteoarthritis, although only half ever develop symptoms (Altman et al., 1991). 
Notwithstanding, due to the huge amount of persons affected, osteoarthritis is a frequent 
cause of disability (Lawrence et al., 1998). 
Several pharmaceutical approaches, such as analgesics, non steroidal anti – inflammatory 
drugs, COX – 2 inhibitors and steroids (Hochberg et al., 1995), have been proposed, with the 
aim of reducing pain and maintaining and / or improving joint function. However, none of 
these options has shown to delay the progression of osteoarthritis or reverse joint damage. 
In addition, the incidence of adverse reactions to these drugs increases with age. Data from 
epidemiological studies consistently show that the risk of gastro – intestinal complications is 
very high and largely dose – dependent (Griffin MR et al., 1991 ; Smalley & Griffin, 1996). It is 
well known that non steroidal anti – inflammatory drugs, as well as selective COX – 2 
inhibitors, may cause renal failure, hypertension and water retention and have a thrombotic 
potential, especially for high doses and long term treatments (Roughead et al., 2008; Savage, 
2005). Corticosteroids are burdened with relevant adverse reactions, when given systemically, 
and therefore are usually administered by intra – articular injection in patients who fail to 
respond to other conservative measures; in particular, patients with joint effusions and local 
tenderness may have greater benefit from this option (Flanagan et al., 1988). 
Although it has been established that corticosteroid injections are relatively safe, there are 
concerns regarding their possible adverse effects, following repeated injections. These effects 
include local tissue atrophy, particularly when small joints are injected, long – term joint 
damage, due to reduced bone formation, and risk of infection, due to suppression of 
adrenocortical function (Mader et al., 2005; Weitoft et al., 2005).  
Considering the limits of therapies at present available, drugs with minimal side effects are 
therefore warranted. 
Viscosupplementation by intra – articular injections of hyaluronic acid has been proposed as 
useful therapeutic option in the treatment of osteoarthritis in different joints (Migliore et al., 
2010). 
Aim of the chapter is to summarize the more significant results of this therapeutic approach, 
reporting the recently published data and focusing attention on issues yet unsolved. 
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2. Synovial fluid  
Synovial fluid is essential for the normal joint functioning : it acts both as a lubricant during 
slow movement (e.g. in walking), and as an elastic shock absorber during rapid movement 
(e.g. in running). It also serves as a medium for delivering nutrition, and transmitting 
cellular signals to articular cartilage.  
Hyaluronic acid, produced by synoviocytes, fibroblasts and chondrocytes, is the major 
chemical component of synovial fluid. The native hyaluronic acid has a molecular weight of 
4 – 10 millions Daltons, and is present in articular fluid in concentration about 0.35 gr / 100 
ml (Weiss & Band, 1995). It is essential for the viscoelastic properties of the fluid because of 
high viscosity, and has a protective effect on articular cartilage and soft tissue surfaces of 
joints (O' Regan et al., 1994; Van den Bekerom et al., 2008). 
In pathological conditions, the concentration and molecular weight of hyaluronic acid are 
reduced, resulting in synovial fluid of lower elasticity and viscosity : the factors which 
contribute to the low concentrations of hyaluronic acid are diluitional effects, reduced 
hyaluronan synthesis and free radical degradation (Van den Bekerom et al., 2006). When 
viscoelasticity of synovial fluid is reduced, the transmission of mechanical force to cartilage 
may increase its susceptibility to damage.  
Therefore, the restoration of the normal articular homoeostasis is the rationale for 
hyaluronic acid administration into osteoarthritic joints. Moreover, being hyaluronic acid a 
physiological component, it is very likely that it may be deprived of adverse reactions, also 
after repeated administrations. 
3. Therapeutic activities of hyaluronic acid 
The direct injection of hyaluronic acid in the joint space allows to reach a proper 
concentration with low doses, favouring a longer permanence in the joint, and therefore the 
therapeutic response. 
Hyaluronic acid preparations have a short half – life; therefore, the long term effects cannot 
solely be attributed to the substitution of molecule itself. The term viscosupplementation 
means  restoration of visco – elastic properties, such as cushioning, lubrication, elasticity 
(Kikuchi et al., 2001), while the term biosupplementation is used to indicate the  restoration 
of joint rheology, anti – inflammatory and anti – nociceptive effects, normalization of 
endogenous hyaluronic acid synthesis, and chondroprotection. These activities explain why 
the clinical efficacy is maintained for several months (Gigante & Callegari, 2010 ; Hiraoka et 
al., 2011; Julovi et al., 2011; Kumahashi et al., 2011). 
In Table 1, the main beneficial effects of hyaluronic acid in osteoarthritis are summarized. 
4. Hyaluronic acid preparations 
At present, preparations with different molecular weight are available (Low and High 
Molecular Weight), which display distinct pharmaceutical effects (Ghosh & Guidolin, 
2002). 
The enhanced penetration of low molecular weight preparations (0.5 – 1.5 millions Dalton) 
through the extracellular matrix of the synovium is thought to maximize the concentration 
and to facilitate the interaction with target synovial cells, so reducing the synovial 
inflammation (Bagga H et al., 2006). 
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ACTION TARGET RESULTS 
Inhibition Lymphocyte transformation
 
SLOW DOWN THE 
PROGRESSION OF JOINT 
DAMAGE 
 
ANTI – INFLAMMATORY 
ACTIVITY 
 
ANTI – NOCICEPTIVE 
EFFECTS 
 
MODIFIED STRUCTURAL 
ORGANIZATION 
TOWARDS NORMAL 
APPEARANCE 
 
Phagocytic activity of macrophages and 
leukocytes
 Adenosine triphosphate levels
 Matrix Metalloproteinase (MMP)
Promotion Release of prostaglandins
 Normalization of native hyaluronan synthesis
 Production of tissue inhibitor of MMP – 1
 Scavenging of free radicals
 Proteoglycans synthesis by chondrocytes
Protective 
Effects on chondrocytes or cartilage explants 
from degradation by enzymes, Interleukin – 1, 
and oxygen – derived free radicals 
Table 1. Beneficial effects of hyaluronic acid (modified from Carpenter & Motley (2008)) 
However, because of the low elastoviscosity of these hyaluronan compounds, compared to 
native hyaluronan in the synovial fluid, interests were shifted to a viscosupplementation 
fluid similar to the native hyaluronic acid. 
Recently, an hyaluronic acid cross – linked preparation (Hylan G – F 20), with high 
molecular weight (6 – 7 millions Dalton), has been developed (Migliore et al., 2010). 
This formulation, by means of its hydrophilic properties, retains higher amounts of fluid in 
articular space; it is also provided by a greater anti – inflammatory activity, as shown by 
studies on migration of inflammatory cells in the joint and on reduced Prostaglandin E 2 
and bradykinin concentration (Goto et al., 1999; Takahashi et al., 1999). Moreover, high 
molecular weight hyaluronic acid is considered more effective in relieving pain, compared 
to low molecular weight hyaluronic acid.  
A novel hyaluronic acid preparation, non – animal stabilised hyaluronic acid (NASHA) 
(Berg & Olsson, 2004) has been manifactured by a two stage procedure : byosinthesis of 
hyaluronic acid by cultured bacteria, followed by a mild stabilization process. Stabilisation 
does not change the biochemical properties of hyaluronic acid, but creates bio – compatible 
gel with improved viscoelastic properties and a longer residence time in joint, compared 
with non – stabilised hyaluronic acid preparation. 
Currently, with aim of favouring a longer presence of hyaluronic acid in the joint, long 
acting preparations are under study (Abate et al, 2010). Hopefully, these compounds, with 
better rheological and biological properties, could influence positively the natural history of 
osteoarthritic disease. 
5. Indications to treatment 
Viscosupplementation can be considered when the patient has not found pain relief from 
exercise, physical therapy, weight loss, use of orthotics and analgesics or non steroidal anti – 
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inflammatory drugs. Other indications may be the intolerance to drugs or the use of 
multiple systemic medications, as frequently happens in the elderly (Waddell, 2007). 
The treatment, in general, is offered to patients with intermediate Kellgren – Lawrence  
score (mild osteoarthritis) (Kellgren & Lawrence, 1957), who report better results in term of 
function and pain reduction (Brzusek & Petron, 2005). 
The administration of hyaluronic acid is contraindicated only in patients with known 
hypersensitivity to preparations components; patients with severe osteoarthritis 
(Kellgren – Lawrence score IV) or affected by inflammatory musculoskeletal diseases 
(rheumatoid arthritis, chondrocalcinosis, psoriasis, gout), may have limited benefit 
(Waddell, 2007). 
6. Infiltration techniques 
Intra – articular injection of hyaluronic acid must be performed in sterile conditions, to 
minimize the risk of inflammatory complications (i.e. septic arthritis). 
Moreover, the use of “image – guided” infiltration techniques is mandatory; indeed, when 
joint infiltration is performed blindly, the failure rate is high, and the drug may be 
administered in the para – articular space. In this case, treatment loses its efficacy and side 
effects, mainly pain, frequently occur (Pourbagher et al., 2005; Zwar et al., 2004). 
The ultrasound – guided injection, compared with fluoroscopy, has several advantages : it 
is simple, fast, economic and safe; it does not require the use of contrast media, allowing 
the infiltration in patients intolerant to iodized contrasts. It can be repeated without 
limits, allows an easy visualization of fluid in the articular recess (which may be 
aspirated) (Figure 1), and shows how narrow is the articular space.  
 
 
F = Femur 
Fig. 1. Ultrasound imaging (longitudinal scan). An effusion (*) is present inside the articular 
space of knee joint. 
Moreover, it is able to show the position of the needle, and, by means of continuous Color 
Doppler monitoring, to evaluate its distance from vessels. Finally, ultrasound technique 
allows the visualization of the viscous fluid injected inside the joint (Migliore et al., 2004). 
In figure 2, an example of intra – articular injections of hip joint is presented. 
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FH = Femoral head; Fn = Femoral neck; 1 = articular space; Arrows = articular capsule 
Fig. 2. Ultrasound guided injection of hip joint (longitudinal scan). Before the injection, hip 
joint is evaluated (left panel). After the injection (right panel), the correct placement of 
hyaluronic acid (calipers) is confirmed by the presence of hyperechoic material inside the 
articular space.  
7. Clinical results 
In this section we report the main results obtained with hyaluronic acid in the treatment of 
osteoarthritis in different joints. 
7.1 Knee osteoarthritis 
Viscosupplementation with hyaluronic acid in knee osteoarthritis has been approved by 
Food and Drugs Administration (Hunter & Lo, 2008).  
Recent guidelines are based on a meta – analysis, including 5257 participants to 40 
Randomized Controlled Trials (Curran, 2010; National Collaborating Center for Chronic 
Conditions at the Royal College of Physicians, 2008). These studies were performed, single 
or double – blind, with different types of hyaluronic acid (low and high molecular weight) 
against placebo. The number of injections ranged from 3 to 5 weekly, with a maximum of 11 
in 23 weeks, the doses from 15 to 60 mg and the trials length from 4 weeks to 18 months.  
Pain was evaluated by means of Visual Analogic Scale and Western Ontario and McMaster 
Universities Osteoarthritis Index, at rest and under different load conditions. A minor 
number of studies evaluated the functional outcomes (Western Ontario and McMaster 
Universities Osteoarthritis Index [physical function], Lequesne Index, Range of motion), the 
subjective global assessment and the quality of life of the patients. The results of the 
majority of studies are in favour of hyaluronic acid, although in several randomized 
controlled trials no significant differences have been found in comparison with intra – 
articular placebo. The percentages of improvement from baseline, in all the outcomes 
measures, were 28 % to 54 % for pain, and 9 % to 32 % for function, and were similar in the 
trials where low molecular weight or high molecular weight hyaluronic acid were used 
(Aggarwal & Sempowski, 2004; Divine et al., 2007; Waddel 2007). However, the number of 
injection needed was in general lower for high molecular weight preparation and this is not 
a negligible advantage for the patients. 
A recent systematic review has compared the post – intervention time course of the effects 
of hyaluronic acid and corticosteroid (the “therapeutic trajectory”) (Bannuru et al., 2009). 
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This meta analysis highlights the therapeutic trajectory of hyaluronic acid for knee 
osteoarthritis pain over six months following the intervention. From baseline to week 4, 
intra – articular corticosteroid appear to be relatively more effective than hyaluronic acid. By 
week 4 the two approaches have equal efficacy, but beyond week 8 hyaluronic acid has 
greater efficacy. 
It should be observed that the benefit is not equally distributed among patients, some of 
them being non – responders to therapy. The characteristics of responders, at present, have 
not been clearly identified, but some authors claim that a greater benefit may be obtained in 
patients with low grade osteoarthritis (Dagenais et al., 2006). On the contrary, age does not 
influence the therapeutic response (Abate et al., 2008). 
7.2 Hip osteoarthritis 
The number of studies about viscosupplementation of hip osteoarthritis is limited, when 
compared with studies in knee osteoarthritis. The reasons can be the deeper localization of 
this joint, and the proximity of femoral vessels and nerves. 
Moreover, the level of evidence for most of these studies is low, because they are cohort 
studies and lack of a reference group (Abate et al., 2010), a score I (i.e. the highest level of 
evidence), according to the Center for Evidence Based Medicine criteria (Fletcher & Sackett, 
1979), having been assigned only to Tikiz's (Tikiz et al., 2005) and Qvistgaard's (Qvistgaard 
et al., 2006) studies. 
A new randomized controlled three – arm study, comparing intra – articular injection of 
hyaluronic acid, corticosteroid and bupivacaine, is in progress; this trial will hopefully 
provide robust information on the advantages of drugs towards the simple anaesthetic 
treatment (Colen et al., 2010). 
In the published studies, several hyaluronic acid compounds were used. The number of 
injections ranged from 1 to 3 for each patients, and only in few cases 4 or 5 injections were 
performed. In general, the injections number was lower for high molecular weight 
preparations. The length of treatments and the outcome measures were similar to those used 
in knee randomized controlled trials. 
All the trials have shown a reduction of pain, which, in general, becomes evident within 3 
months and persists in the following months. Only few studies report a precocious 
reduction of the pain : within a week, according to Brocq (Brocq et al., 2002) (– 27 %), and 
within the first 2 – 4 weeks according to Qvistgaard (Qvistgaard et al., 2001) (– 14 % and – 32 
%, respectively). The positive effects on pain after 1 – 3 months range from – 16.1 % to – 52.2 
% (mean – 37.2 %), whereas, overall, the mean Visual Analogic Scale score decreases about 
49 % after 3 – 6 months (range 31 – 80 %) (Abate et al., 2008). 
Therefore, it seems that the benefit increases in the long term. However, it must be 
underlined that only few studies report longer follow – up periods : at 12 (Migliore et al., 
2005) and at 18 months (Migliore et al., 2006a), with persistent benefit on the pain (VAS – 
36.4 %). Besides the reduction of pain, also the articular function is improved. These positive 
effects have been observed using different evaluation scales : + 11 % in the Harris Hip Score, 
+ 32 – 45 % in Western Ontario and McMaster Universities Osteoarthritis Index score, + 45 
% in Lequesne Index, and + 95 % in American Academy of Orthopaedic Association Lower 
Limb Core Scale (Abate et al., 2008). A further observation, which confirms the previous 
data, is the reduction of non steroidal anti – inflammatory drugs consumption (Migliore et 
al., 2011).  
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7.3 Ankle osteoarthritis 
Only few studies have been performed in ankle osteoarthritis and, among these, four were 
randomized / controlled trials (level of evidence 1) (Carpenter & Motley, 2008; Cohen et al., 
2008; Karatosun et al., 2008; Salk et al., 2005, 2006), while seven studies (Hanson et al., 1999; 
Luciani et al., 2008; Mei – Dan et al., 2010; Sun et al., 2006; Valiveti et al., 2006;  Witteveen et 
al., 2008, 2010) were case series (level of evidence 4). 
In all these studies, patients suffering from post – traumatic Kellgreen – Lawrence grade II – 
IV ankle osteoarthritis were enrolled. Different hyluronic acid preparations were used, and 
patients received 1 up to 5 injections. Only in one study, the injections were performed by 
means of image guidance (fluoroscopy) (Cohen et al., 2008). Clinical benefit was evaluated 
by means of different scales (Visual Analogic Scale, Ankle Osteoarthritis Scale, American 
Orthopaedic Foot and Ankle Society, Short Form – 12, Short Form – 36, Western Ontario and 
McMaster Universities Osteoarthritis Index), and the follow – up period varied from 6 to 18 
months. 
In studies performed without control group (Hanson et al., 1999; Luciani et al., 2008; Mei – 
Dan et al., 2010; Sun et al., 2006; Valiveti et al., 2006;  Witteveen et al., 2008, 2010) (Table 
2), an improvement in all the outcome measures was reported, with the effect lasting for 
18 months (Luciani et al., 2008). However, it is not clear from reports whether the pain 
reduction was clinically significant, or could be ascribed only to a placebo effect. In 
addition, the lack of controls does not allow definitive conclusions on the efficacy of 
hyaluronic acid. 
 
Authors Patients Age HA Dose Follow up Results 
Mei – Dan 15 43 LMW 1x5 wks 7 months Positive 
Sun 75 50 LMW 1x5 wks 6 monhts Positive 
Luciani 21 45 HMW 1x3 wks 3 monhts Positive 
Witteveen(2008) 55 41 HMW 1 or 2 6 – 9 months Positive 
Witteveen(2010) 26 43 HMW 1 or 2 or 3 6 months Positive 
HA = Hyaluronic acid; LMW = Low Molecular Weight; HMW = High Molecular Weight 
Table 2. Case series studies on ankle osteoarthritis. Valiveti (2006) and Hanson (1999) 
studies' are not reported due to the small number of cases. 
The level 1 evidence studies are more qualified to assess the therapeutic efficacy, but also 
these trials show several limitations (e.g., no information on the actual number of potential 
patients, no clear patients randomization, imbalance of baseline characteristics between 
intervention and control groups, statistical weakness), and therefore have to be considered 
as low quality studies. 
In these studies (Carpenter & Motley, 2008; Cohen et al., 2008; Karatosun et al., 2008; Salk et 
al., 2005, 2006) (Table 3), the patients treated with hyaluronic acid showed a significant 
decrease in pain and disability at 6 months (Cohen et al., 2008; Salk et al., 2005, 2006), with 
the effects lasting 12 – 13 months (Carpenter & Motley, 2008; Karatosun et al., 2008). Besides 
the reduction of these parameters, an improvement in ankle sagittal range of motions, and 
gait quality was observed (Karatosun et al., 2008). 
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Authors Patients Age HA Dose Control Follow up HA vs Controls 
Carpenter 26 55 HMW 1x3 wks Arthroscopy 13 months > HA (moderate) 
Cohen 30 49 LMW 1x5 wks Saline 6 months No difference 
Karatosun 30 55 LMW 1x3 wks Exercise 12 months No difference 
Salk 17 58 LMW 1x5 wks Saline 6 months No difference 
Table 3. Randomized controlled trials on ankle osteoarthritis. Salk et al. (2006, 2005)  
presented their results in two different journals. 
In any study the authors found difference between hyaluronic acid and controls groups. In 
particular, in the studies performed by Salk (Salk et al., 2005, 2006) and Cohen (Cohen et al., 
2008), the patients, treated with a 1 – 2 ml phosphate – buffered saline solution injection, 
reported a similar improvement in all parameters evaluated. Analogously, positive results 
were observed in patients, who followed a 6 weeks exercise therapy (muscle strengthening 
and ankle range of motion exercises) (Karatosun et al., 2008), and after arthroscopic lavage 
of osteoarthritic ankle joint (Carpenter & Motley, 2008). 
On the basis of these observations, no clear evidence on the efficacy of hyaluronic acid in 
reducing pain, and improving function, in ankle osteoarthritis, is provided. 
Several factors can explain why viscosupplementation has limited efficacy in ankle 
osteoarthritis. 
Ankle joint, anatomically and functionally, is more complex than other joints, which are 
usually treated with positive results with hyaluronic acid (hip, knee) (Saltzman et al., 
2005). 
Another possible reason of the limited benefit of hyaluronic acid can be related to its use 
mostly in post – traumatic osteoarthritis (Zhang & Jordan, 2010), which has a pathogenesis  
quite different from that of primary degenerative osteoarthritis. 
Finally, it must be considered that all studies (Carpenter & Motley, 2008; Hanson et al., 1999; 
Karatosun et al., 2008; Luciani et al., 2008; Mei – Dan et al., 2010; Salk et al., 2005, 2006; Sun 
et al., 2006; Valiveti et al., 2006;  Witteveen et al., 2008, 2010), but one (Cohen et al., 2008), 
were performed blindly, with any imaging guidance. This can be a valid explanation of 
several unsatisfactory results, because there is evidence that about one third of intra – 
articular injections are not delivered into the intra – articular cavity, when performed 
without a visual aid (Cunnington et al., 2010). 
At this regard, ankle joint presents many technical difficulties of injecting intra – articularly, 
due to its complex anatomy, further complicated from the osteoarthritic joint changes (Woo 
et al., 2010). 
7.4 Gleno – Humeral osteoarthritis 
Hyaluronic acid is effective and well tolerated for the treatment of osteoarthritis and 
persistent shoulder pain refractory to other standard non operative interventions (Andrews, 
2005).  
Several authors (Blaine et al., 2008; Leardini et al., 1988) report that both 3 and 5 weekly 
intra – articular injections of low molecular weight hyaluronic acid provide significant 
improvement in terms of shoulder pain (Visual Analogic Scale score on movement), with 
the effects lasting 7 – 26 weeks (Blaine et al., 2008). 
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Similarly, in a 6 months follow – up studies (Merolla et al., 2011; Silverstain et al., 2007), a 
significant reduction in Visual Analogic Scale pain score was also provided with 3 weekly 
intra – articular high molecular weight hyaluronic acid (Hylan G – F 20) injections. In 
addition, most of the patients experienced an improvement in the shoulder function score 
and in the activities of daily living (Itokazu & Matsunaga, 1995; Merolla et al., 2011). 
A recent study comparing Hylan G – F 20 versus 6 methylprednisolone acetate shows that 
hyaluronic acid is effective in reducing pain for up to 6 months, whereas corticosteroid 
injections result in improvement at 1 month only (Merolla et al., 2011). 
Finally, the efficacy of hyaluronic acid has been demonstrated in the treatment of different 
shoulder diseases, such as subacromial bursitis, adhesive capsulitis and rotator cuff tear 
(Blaine et al., 2008; Calis et al., 2006; Fernandez – Palazzi et al., 2002; Rovetta & 
Monteforte, 1998; Tamai et al., 2004), with positive results on pain, joint mobility and 
shoulder function. 
7.5 Carpo – Metacarpal osteoarthritis 
Because carpo – metacarpal joint is essential for the closure of the first web, a loss of function 
causes an alteration of the thumb – index pinch, and therefore can lead to functional 
impairment (Spacek et al., 2004).  
Several conservative treatments have been proposed (corticosteroids, non steroidal anti – 
inflammatory drugs, prolotherapy, splinting), but none of these has shown to delay the 
progression of osteoarthritis or reverse joint damage (Fuchs et al., 2006). 
Recent studies have investigated the efficacy of hyaluronic acid in the treatment of carpo – 
metacarpal osteoarthritis (Figure 3) and positive results have been reported by most of the 
authors. 
 
 
MC = Metacarpal bone 
Fig. 3. Ultrasound features of carpo – metacarpal osteoarthritis (right panel) : the cortex of 
the trapezium bone (T) is irregular and an osteophyte is present (arrow); mild articular 
effusion (*) can be also appreciated. In left panel, normal features are reported.  
In particular, an early improvement in Visual Analogic Scale score was observed after 2 
weeks post treatment (Heyworth et al., 2008), with the effects lasting until 1 – 3 months 
(Coaccioli et al., 2006; Roux et al., 2007; Schumacher et al., 2004; Stahl et al., 2005). The long 
term effects of hyaluronan were demonstrated only in few studies (Fuchs et al., 2006; 
Heyworth et al., 2008;), in which the pain relief was reported at 6 months (Di Sante et al., 
2011). 
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Beside pain reduction, also grip strength improved significantly in some studies (Migliore et 
al., 2010), although these effects were achieved slowly, with better results observed at 6 
months (Fuchs et al., 2006; Heyworth et al., 2008; Stahl et al., 2005). 
In our experience (Table 4), a single ultrasound guided injection of hyaluronic acid is 
effective in treatment of carpo – metacarpal osteoarthritis (Salini et al., 2009). After therapy 
the Visual Analogic Scale pain score, both at rest and during common daily activities, 
decreases, while the hand function and strength are improved. The best improvement is 
observed in the pulp pinch strength, because the carpo – metacarpal joint is strongly 
stressed in this movement (Spacek et al., 2004), and therefore a better mobility and a 
reduction of pain in the joint allow evident increase in performance.  
 
 Baseline Follow – up p 
VAS rest 1,8 ± 1 0,5 ± 0,6 < 0.001 
VAS activities 8 ± 0,9 4,1 ± 1,4 < 0.001 
Dreiser Index 18,5 ± 3,3 20,7 ± 2,7 < 0.004 
Hand grip (Kg) 19,3 ± 16,5 19,6 ± 16,1 0.13 
Lateral grip (Kg) 9,5 ± 4 10 ± 3,3 0.17 
Pulp grip (Kg) 4,1 ± 1,4 5,4 ± 1,3 < 0.001 
NSAIDs (n. of subjects) 16 7  
NSAIDs (tablets / week) 2,4 ± 1,9 1,1 ± 1,3 < 0.02 
NSAID =  Non Steroidal Anti – Inflammatory Drug; VAS = Visual Analogic Scale 
Table 4. Positive results of hyaluronic acid on pain and hand function 
7.6 Temporo-mandibular joint 
At present, 19 studies have been published, and only 8 were randomized and controlled 
trials (Manfredini et al., 2010). All studies reported a decrease in pain levels 
independently by the patients’ disorder and by the adopted injection protocol. Positive 
outcomes were maintained over the follow – up period, which ranged largely from 15 
days to 24 months. The superiority of hyaluronic acid injections was shown only against 
placebo saline injections, but outcomes were comparable with those achieved with 
corticosteroid injections. 
Interestingly, in an experimental model of arthropatic temporomandibular joint, El – Hakim 
and Elyamani (El – Hakim & Elyamani 2011) found, after repeated intra – articular injections 
of hyaluronic acid, an increase in the thickness of the cartilagineous layer, suggesting that 
hyaluronic acid can inhibit the progression of osteoarthritic changes. 
A recent study, aiming to identify predictors for treatment efficacy, has shown that only 
unilateral temporomandibular joint osteoarthritis predicts better the benefit  
(Guarda – Nardini et al., 2011), while sex, age, pain duration are not provided of 
predictive power.  
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7.7 Other joints 
Encouraging results have been reported in the treatment of painful hallux rigidus (Pons et 
al., 2007), of sacroiliac joint syndrome (Calvillo et al., 2000; Srejic et al., 1999), and of nerve 
root adhesion after lumbar intervertebral disco herniation (Wang et al., 2002). 
In the treatment of elbow osteoarthritis the results are inconclusive. Positive effects have 
been observed only in two small studies (Fernandez – Palazzi et al., 2002; Hanson, 1999), 
while, in a larger study (18 patients), intra – articular hyaluronic acid was not effective in the 
treatment of post – traumatic osteoarthritis of the elbow (Van Brakel & Eygendaal, 2006). 
Controversial results have been observed also in the treatment of spine osteoarthritis. Fuchs 
et al. (Fuchs et al., 2005) reported significant pain relief and improved quality of life, also in 
the long term, in patients affected from facet joints osteoarthritis with chronic non radicular 
pain in the lumbar spine. However, these results are not in agreement with a recent study by 
Cleary et al. (Cleary et al., 2008), who have not seen any benefit of viscosupplementation in 
the management of symptomatic lumbar facet osteoarthritis. 
8. Side effects 
Several factors may contribute to the occurrence of side effects : among them, the 
characteristics and amount of hyaluronic acid preparation injected, the number of 
injections, the skill of the operator, the technique used, the local and systemic tissues 
reactions. 
In quite all the clinical trials, no general side effects were observed, and only few patients 
reported a sensation of heaviness and pain in their joint after injection (Abate M, 2009). 
These effects were more frequent in studies performed in blind conditions compared to 
those performed under imaging guidance. No differences were observed in relation to 
hyaluronic acid preparation used or to the number of injections (Abate M, 2008).  
Side effects usually disappeared after 2 – 7 days without any therapeutic intervention and 
did not limit basic or instrumental activities of daily living. 
Vascular or nervous complications were never reported, neither gout, chondrocalcinosis, 
sometimes observed after viscosupplementation of the knee (Curran, 2010). 
Septic arthritis or aseptic synovial effusion occurred in a very limited number of cases 
(Brocq et al., 2002; Chazerain et al., 1999). 
9. Hyaluronic acid vs corticosteroids 
Intra – articular corticosteroids are the alternative choice to hyaluronic acid for treatment of 
osteoarthritis. Therefore it is important to evaluate the studies, which compared these 
treatment modalities. The large majority of comparison studies has been performed between 
different hyaluronic acid preparations and steroids (methylprednisolone, triamcinolone) 
(Bellamy et al., 2006). 
In several studies, better results were observed after hyaluronic acid injection (Cohen et al., 
2008; Fuchs et al., 2005, 2006), in other no significant difference was found (Chazerain et al., 
1999; Qvistgaard et al., 2006). Steroids however offered the best results on joints with 
inflammatory effusions (Atchia et al., 2011). 
Only one study compared the clinical efficacy of hyaluronic acid versus corticosteroids and 
placebo in hip osteoarthritis. This very large trial, including 101 patients, did not show 
significant differences between the treatments in all the outcome measures, after 3 months 
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(Qvistgaard et al., 2006). However, within this time period, an improvement was found, 
which resulted clearly evident in the steroid group and moderate in hyaluronic acid group, 
compared to placebo (Qvistgaard et al., 2006). 
A comparison study on the efficacy of Hylan G – F 20 versus 6 – methylprednisolone acetate 
in shoulder osteoarthritis shows that hyaluronic acid is effective in reducing pain for up to 6 
months, whereas corticosteroids injections result in an improvement at 1 month only 
(Merolla et al., 2011). 
Analogously, Bannuru et al. (Bannuru et al., 2009) have shown in the treatment of knee 
osteoarthritis that intra – articular corticosteroids appear to be relatively more effective for 
pain that hyaluronic acid in the first four weeks, but in the long term hyaluronic acid has 
greater efficacy. 
In carpo – metacarpal joint osteoarthritis, a rapid pain relief was observed after 
triamcinolone or methylprednisolone injections (after 2 – 4 weeks), but disappeared soon 
after (Heyworth et al., 2008). Positive effects were achieved with hyaluronic acid more 
slowly, but were long – lasting and persisted 6 months after end of treatment period (Fuchs 
et al., 2006). 
Also for the treatment of temporomandibular joint osteoarthritis, the comparison between 
corticosteroids and hyaluronic acid has shown that both compounds reduce pain and 
improve articular function (Manfredini et al., 2010).  
10. Conclusions 
On the basis of the published trials, we may affirm that viscosupplementation therapy with 
hyaluronic acid is a safe and effective method in the management of osteoarthritis resistant 
to conventional therapies. This treatment has been approved by Food and Drug 
Administration for knee osteoarthritis, whereas for the other osteoarthritic joints there are 
promising results but not conclusive evidence. 
The use of hyaluronic acid is mainly recommended when non steroidal anti – inflammatory 
drugs are contraindicated or badly tolerated, when non steroidal anti – inflammatory drugs 
or corticosteroid are inefficacious, or in young patients candidate to prosthesis. 
Viscosupplementation significantly reduces pain within 3 months and this beneficial effect 
is maintained in the long term (12 – 18 months). The articular function is improved and, 
therefore, patients can rapidly come back to work and to social activities. 
Only few trials have shown a very early improvement, which has been related to the 
lubricating effect of hyaluronate in “dry” joints, as reported in studies of 
viscosupplementation in knee osteoarthritis, and / or to a short term placebo effect (Brocq et 
al., 2002). 
The reduction in non steroidal anti – inflammatory drugs consumption is another 
important clinical achievement with significant health economic consideration 
(Sturkenboom et al., 2002). Not only direct costs (non steroidal anti – inflammatory drugs 
purchasing), but also the indirect costs associated with management of non steroidal anti 
– inflammatory drugs side effects, are saved. Cost – benefit analysis is difficult in 
comparison with corticosteroids. Corticosteroids doses are cheaper than hyaluronic acid 
preparation, but the efficacy of these drugs seems to last less longer than hyaluronic acid 
preparations, with more relevant side effects, which can offset the initial saving 
(Qvistgaard et al., 2006). 
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Patients with mild morphological alterations, and with preserved articular space, are 
more responsive to treatment (Brocq et al., 2002; Gaston et al., 2007; Van den Bekerom et 
al., 2006); the results are less encouraging in patients with severe osteoarthritis (Kellgreen 
– Lawrence IV), only few studies reporting a good therapeutic effects (Migliore et al., 
2006b). 
Articular effusion usually is associated to a reduced therapeutic efficacy due to the “dilution 
effect” of the drug (Qvistgaard et al., 2006). In this situation, a better therapeutic response is 
observed with intra – articular corticosteroids, probably linked to their anti – inflammatory 
activity (Qvistgaard et al., 2006). 
The better biological activity, shown by high molecular weight hyaluronic acid preparations 
in vitro, has not been confirmed in clinical trials (Tikiz et al., 2005). In fact, the percentage of 
improvement in all the outcomes measures is similar with low molecular weight and high 
molecular weight hyaluronic acid preparations (Caglar – Yagchi et al., 2005). An advantage 
of high molecular weight hyaluronic acid may be the reduced number of the injections 
needed to obtain the therapeutic effect. 
When the therapy is delivered by appropriately trained doctors, under strict imaging 
guidance, viscosupplementation is a safe procedure, without any systemic or local side 
effect, excluding the pain of the injection and a sensation of heaviness for few hours / 
days after treatment. It is likely that persistent pain and joint swelling or major 
complications, such as septic arthritis may occur when injection is not properly 
performed. Even experienced clinicians can miss intra – articular placement of the drug, 
especially in small joints (Gaffney et al., 1995; Jones et al., 1993). The very high 
tolerability of the preparation allows the contemporary use of other drugs, which is very 
important in elderly patients with comorbid conditions and poli – pharmaceutical 
treated. 
Although these promising results, several questions are still opened. 
Inclusion and exclusion criteria vary largely in different studies and therefore the 
characteristics of patients, who are better responsive to treatment, are not clearly defined. 
The identification of these patients is, therefore, strongly recommended. 
No consensus exist about the doses of hyaluronic acid, the interval between doses and the 
number of injections, which are more effective in the different clinical situations. A 3 – 5 
doses regimen is usually recommended, but studies which compare different treatment 
schedules are lacking (Tikiz et al., 2005).  
It is also debated whether high molecular weight hyaluronic acid has to be preferred to low 
molecular weight hyaluronic acid. The better biological activity, showed by high molecular 
weight hyaluronic acid preparations in vitro, has not been confirmed in clinical trials (Tikiz 
et al., 2005). Some authors prefer to use high molecular weight hyaluronic acid because 
these preparations have a longer half – life time, so that the number of the injections needed 
to obtain the therapeutic effect may be reduced. 
Interpretation of result is made difficult by the different degree of severity of osteoarthritis, 
genetic and biological characteristics of patients enrolled in the studies and by concurrent 
therapies with other drugs and rehabilitation treatments (Brocq et al., 2002; Conrozier et al., 
2003; Migliore et al., 2003; Tikiz et al., 2005; Vad et al., 2003). 
Finally, it must be remembered that there is a strong placebo effect from joint injection, 
which may cause a nearly 30 % reduction in pain relief during the first 2 weeks (Brocq et al., 
2002; Egsmose et al., 1984; Kirwan, 2001; Ravaud et al., 1999; Tikiz et al., 2005). 
www.intechopen.com
  
Osteoarthritis – Diagnosis, Treatment and Surgery 
 
114 
11. References 
Abate, M., Pulcini, D., Di Iorio, A. & Schiavone, C. (2010). Viscosupplementation with intra- 
articular hyaluronic acid for treatment of osteoarthritis in the elderly. Curr Pharm  
Des, Vol.16, No.6, pp. 631-640 
Abate, M., Pelotti, P., De Amicis, D., Di Iorio, A., Galletti, S. & Salini, V. (2008).  
Viscosupplementation with hyaluronic acid in hip osteoarthritis (a review). Ups J  
Med Sci, Vol.113, No.3, pp. 261-277 
Aggarwal, A. & Sempowski, IP. (2004). Hyaluronic acid injections for knee osteoarthritis.  
Systematic review of the literature. Can Fam Physician, Vol.50, pp. 249-256 
Altman, R., Alarcon, G., Appelrouth, D., Bloch, D., Borenstein, D., Brandt, K., Brown, C.,  
Cooke, TD., Daniel, W., Feldman, D. & et al. (1991). The American College of  
Rheumatology criteria for the classification and reporting of osteoarthritis of the  
hip. Arthritis Rheum, Vol.34, No.5, pp. 505-514 
Andrews, JR. (2005). Diagnosis and treatment of chronic painful shoulder: review of  
nonsurgical interventions. Arthroscopy, Vol.21, No.3, pp. 333-347 
Atchia I, Kane D, Reed MR, Isaacs JD, Birrell F. (2011). Efficacy of a single ultrasound-
guided  injection for the treatment of hip osteoarthritis. Ann Rheum Dis, Vol.70, 
No.1, pp. 110-116 
Bagga, H., Burkhardt, D., Sambrook, P. & March, L. (2006). Longterm effects of intraarticular  
hyaluronan on synovial fluid in osteoarthritis of the knee. J Rheumatol, Vol. 33,  
No.5, pp. 946-950 
Bannuru, RR., Natov, NS., Obadan, IE., Price, LL., Schmid, CH. & McAlindon, TE. (2009).  
Therapeutic trajectory of hyaluronic acid versus corticosteroids in the treatment of  
knee osteoarthritis: a systematic review and meta-analysis. Arthritis Rheum, Vol.61,  
No.12, pp. 1704-1711 
Bellamy, N., Campbell, J., Robinson, V., Gee, T., Bourne, R. & Wells, G. (2006).  
Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane  
Database of Systematic Revues, Vol.19, No.2 
Berg, P. & Olsson, U. (2004). Intra-articular injection of non-animal stabilised hyaluronic 
acid (NASHA) for osteoarthritis of the hip: a pilot study. Clin Exp Rheumatol, Vol.22,  
No.3, pp. 300-306 
Blaine, T., Moskowitz, R., Udell, J., Skyhar, M., Levin, R., Friedlander, J., Daley, M. &  
Altman, R. (2008). Treatment of persistent shoulder pain with sodium hyaluronate:  
a randomized, controlled trial. A multicenter study. J Bone Joint Surg Am, Vol.90,  
No.5, pp. 970-979 
Brocq, O., Tran, .G, Breuil, V., Grisot, C., Flory, P. & Euller-Ziegler, L. (2002). Hip  
osteoarthritis: short-term efficacy and safety of viscosupplementation by hylan G-F  
20. An open-label study in 22 patients. Joint Bone Spine, Vol.69, No.4, pp. 388-391 
Brzusek, D. & Petron, D. (2008).Treating knee osteoarthritis with intra-articular hyaluronans.  
Curr Med Res Opin, Vol.24, No.12, pp. 3307-3322  
Caglar-Yagci, H., Unsal, S., Yagci, I., Dulgeroglu, D. & Ozel, S. (2005). Safety and efficacy of  
ultrasound-guided intra-articular hylan G-F 20 injection in osteoarthritis of the hip:  
a pilot study. Rheumatol Int, Vol.25, No.5, pp. 341-344 
www.intechopen.com
 Hyaluronic Acid in the Treatment of Osteoarthritis: What is New 
 
115 
Calis, M., Demir, H., Ulker, S., Kirnap, M., Duygulu, F. & Calis, HT. (2006). Is intraarticular  
sodium hyaluronate injection an alternative treatment in patients with adhesive  
capsulitis? Rheumatol Int, Vol.26, No.6, pp. 536-540 
Calvillo, O., Skaribas, I. & Turnipseed, J. (2000). Anatomy and pathophysiology of the  
sacroiliac joint. Curr Rev Pain, Vol.4, No.5, pp. 356-361 
Carpenter, B. & Motley, T. (2008). The role of viscosupplementation in the ankle using hylan  
G – F 20. Journal of Foot & Ankle Surgery, Sep-Oct, Vol.47, No.5, pp. 377-384 
Chazerain, P., Rolland, D., Cordonnier, C. & Ziza, JM. (1999). Septic hip arthritis after  
multiple injections into the joint of hyaluronate and glucocorticoid. Rev Rhum Engl  
Ed, Vol.66, No.7-9, pp. 436 
Cleary, M., Keating, C. & Poynton, AR. (2008). Viscosupplementation in lumbar facet joint  
arthropathy: a pilot study. J Spinal Disord Tech, Vol.21, No.1, pp. 29-32 
Coaccioli, S., Pinoca, F. & Puxeddu, A. (2006). Short term efficacy of intra-articular injection  
of hyaluronic acid in osteoarthritis of the first carpometacarpal joint in a  
preliminary open pilot study. Clin Ter, Vol.157, No.4, pp. 321-325 
Cohen, MM., Altman, RD., Hollstrom, R., Hollstrom, C., Sun, C. & Gipson, B. (2008). Safety  
and efficacy of intra – articular sodium hyaluronate (Hyalgan) in a randomized,  
double – blind study for osteoarthritis of the ankle. Foot and Ankle International,  
Vol.29, No.7, pp. 657-663 
Colen, S., van den Bekerom, MP., Bellemans, J. & Mulier, M. (2010). Comparison of intra- 
articular injections of hyaluronic acid and corticosteroid in the treatment of  
osteoarthritis of the hip in comparison with intra-articular injections of  
bupivacaine. Design of a prospective, randomized, controlled study with blinding  
of the patients and outcome assessors. BMC Musculoskelet Disord, Vol.11, pp. 264 
Conrozier, T., Bertin, P., Mathieu, P., Charlot, J., Bailleul, F., Treves, R., Vignon, E. &  
Chevalier, X. (2003). Intra-articular injections of hylan G-F 20 in patients with  
symptomatic hip osteoarthritis: an open-label, multicentre, pilot study. Clin  Exp 
Rheumatol, Vol.21, No.5, pp. 605-610 
Cunnington, J., Marshall, N., Hide, G., Bracewell, C., Isaacs, J., Platt, P. & Kane, D. (2010). A  
randomized, double – blind, controlled study of ultrasound – guided corticosteroid  
injection into the joint of patients with inflammatory arthritis. Arthritis Rheum, Jul,  
Vol. 62, No.7, pp. 1862-1869 
Curran, MP. (2010). Hyaluronic acid (Supartz®) : a review of its use in osteoarthritis of the  
knee. Drugs Aging, Vol.27, No.11, pp. 925-941 
Dagenais, S. (2006). Intra-articular hyaluronic acid (viscosupplementation) for knee  
osteoarthritis. Issues Emerg Health Technol, Vol.94, pp. 1-4 
Divine, JG., Zazulak, BT. & Hewett, TE. (2007). Viscosupplementation for knee 
osteoarthritis:  a systematic review. Clin Orthop Relat Res, Vol.455, pp. 113-122 
Di Sante, L., Cacchio, A., Scettri, P., Paoloni, M., Ioppolo, F. & Santilli, V. (2011). Ultrasound- 
guided procedure for the treatment of trapeziometacarpal osteoarthritis. Clin  
Rheumatol, Mar 22 
Egsmose, C., Lund, B. & Bach, AR. (1984). Hip joint distension in osteoarthrosis. A triple- 
blind controlled study comparing the effect of intra-articular indoprofen with  
placebo. Scand J Rheumatol, Vol.13, No.3, pp. 238-242 
www.intechopen.com
  
Osteoarthritis – Diagnosis, Treatment and Surgery 
 
116 
El-Hakim, IE. & Elyamani, AO. (2011). Preliminary evaluation of histological changes found  
in a mechanical arthropatic temporomandibular joint (TMJ) exposed to an intra- 
articular Hyaluronic acid (HA) injection, in a rat model. J Craniomaxillofac Surg, Jan  
7 
Fernandez-Palazzi, F., Viso, R., Boadas, A., Ruiz-Saez, A., Caviglia, H. & De Bosch, NB.  
(2002). Intra-articular hyaluronic acid in the treatment of haemophilic chronic  
arthropathy. Haemophilia, Vol.8, No.3, pp. 375-381 
Flanagan, J., Casale, FF., Thomas, TL. & Desai, KB. (1988). Intra-articular injection for pain  
relief in patients awaiting hip replacement. Ann R Coll Surg Engl, Vol.70, No.3, pp.  
156-157 
Fletcher, B. & Sackett, D. (1979). Canadian task force on the periodic health esamination: the  
Periodic Health Examination. CMAJ, Vol.121, pp. 1193-1254 
Fuchs, S., Monikes, R., Wohlmeiner, A. & Heyse, T. (2006). Intra-articular hyaluronic acid  
compared with corticoid injections for the treatment of rhizarthrosis. Osteoarthritis  
Cartilage, Vol.14, No.1, pp. 82-88 
Fuchs, S., Erbe, T., Fischer, HL. & Tibesku, CO. (2005). Intraarticular hyaluronic acid versus  
glucocorticoid injections for nonradicular pain in the lumbar spine. J Vasc Interv  
Radiol, Vol.16, No.11, pp. 1493-1498 
Gaffney, K., Ledingham, J. & Perry, JD. (1995). Intra-articular triamcinolone hexacetonide in  
knee osteoarthritis: factors influencing the clinical response. Ann Rheum Dis, Vol.54,  
No.5, pp. 379-381 
Gaston, MS., Tiemessen, CH. & Philips, JE. (2007). Intra-articular hip viscosupplementation  
with synthetic hyaluronic acid for osteoarthritis: efficacy, safety and relation to pre- 
injection radiographs. Arch Orthop Trauma Surg, Vol.127, No.10, pp. 899-903 
Ghosh, P. & Guidolin, D. (2002). Potential mechanism of action of intra-articular hyaluronan  
therapy in osteoarthritis: are the effects molecular weight dependent? Semin  
Arthritis Rheum, Vol.32, No.1, pp. 10-37  
Gigante, A. & Callegari, L. (2011). The role of intra-articular hyaluronan (Sinovial) in the  
treatment of osteoarthritis. Rheumatol Int, Vol. 31, No.4, pp. 427-444 
Goto, H., Onodera, T., Hirano, H. & Shimamura, T. (1999). Hyaluronic acid suppresses the  
reduction of alpha2(VI) collagen gene expression caused by interleukin-1beta in  
cultured rabbit articular chondrocytes. Tohoku J Exp Med, Vol.187, No.1, pp. 1-13 
Griffin, MR., Piper, JM., Daugherty, JR., Snowden, M. & Ray, WA. (1991). Non steroidal anti- 
inflammatory drug use and increased risk for peptic ulcer disease in elderly  
persons. Ann Intern Med, Vol.114, No.4, pp. 257-263 
Guarda-Nardini, L., Ferronato, G., Favero, L. & Manfredini, D.(2011). Predictive factors of  
hyaluronic acid injections short-term effectiveness for TMJ degenerative joint  
disease. J Oral Rehabil, Vol.38, No.5, pp. 315-320 
Hanson, EC. (1999). Sodium hyaluronate – application in a community practice. American  
Journal of Orthopaedics, Vol.28, Suppl.11, pp. 11-12 
Heyworth, BE., Lee, JH., Kim, PD., Lipton, CB., Strauch, RJ. & Rosenwasser, MP. (2008).  
Hylan versus corticosteroid versus placebo for treatment of basal joint arthritis: a  
prospective, randomized, double-blinded clinical trial. J Hand Surg [Am], Vol.33,  
No.1, pp. 40-48 
www.intechopen.com
 Hyaluronic Acid in the Treatment of Osteoarthritis: What is New 
 
117 
Hiraoka N, Takahashi KA, Arai Y, Sakao K, Mazda O, Kishida T, Honjo K, Tanaka S, Kubo 
T.  (2011). Intra-articular injection of hyaluronan restores the aberrant expression of  
matrix metalloproteinase-13 in osteoarthritic subchondral bone. J Orthop Res,  
Vol.29, No.3, pp. 354-360 
Hochberg, MC., Altman, RD., Brandt, KD., Clark, BM., Dieppe, PA., Griffin, MR.,  
Moskowitz, RW. % Schnitzer, TJ. (1995). Guidelines for the medical management of  
osteoarthritis. Part II. Osteoarthritis of the knee. American College of  
Rheumatology. Arthritis Rheum, Vol.38, No.11, pp. 1541-1546 
Hunter, DJ. & Lo, GH. (2008). The management of osteoarthritis: an overview and call to  
appropriate conservative treatment. Rheum Dis Clin North Am, Vol.34, No.3, pp.  
689-712 
Itokazu, M. & Matsunaga, T. (1995). Clinical evaluation of high-molecular-weight sodium  
hyaluronate for the treatment of patients with periarthritis of the shoulder. Clin  
Ther, Vol.17, No.5, pp. 946-955 
Jones, A., Regan, M., Ledingham, J., Pattrick, M., Manhire, A. & Doherty, M. (1993).  
Importance of placement of intra-articular steroid injections. BMJ, Vol.307, No.6915,  
pp. 1329-1330 
Julovi, SM., Ito, H., Nishitani, K., Jackson, CJ. & Nakamura, T. (2011). Hyaluronan inhibits  
matrix metalloproteinase-13 in human arthritic chondrocytes via CD44 and P38. J  
Orthop Res, Vol.29, No.2, pp. 258-264 
Karatosun, V., Unver, B., Ozden, A., Ozay, Z. & Gunal, I. (2008). Intra – articular hyaluronic  
acid compared to exercise therapy in osteoarthritis of the ankle. A prospective   
randomized trial with long – term follow – up. Clinical and experimental  
rheumatology, Mar-Apr, Vol.26, No.2, pp. 288-294 
Kellgren, JH. & Lawrence, JS. (1957). Radiological assessment of osteo-arthrosis. Ann Rheum  
Dis, Vol.16, No.4, pp. 494-502 
Kikuchi, T., Yamada, H. & Fujikawa, K. (2001). Effects of high molecular weight hyaluronan  
on the distribution and movement of proteoglycan around chondrocytes cultured  
in alginate beads. Osteoarthritis Cartilage, Vol.9, No.4, pp. 351-356 
Kirwan, J. (2001). Is there a place for intra-articular hyaluronate in osteoarthritis of the knee?  
Knee, Vol.8, No.2, pp. 93-101 
Kumahashi, N., Naitou, K., Nishi, H., Oae, K., Watanabe, Y., Kuwata, S., Ochi, M., Ikeda, M.  
& Uchio, Y. (2011). Correlation of changes in pain intensity with synovial fluid  
adenosine triphosphate levels after treatment of patients with osteoarthritis of the  
knee with high-molecular-weight hyaluronic acid. Knee, Vol.18, No.3, pp. 160-164 
Lawrence, RC., Helmick, CG., Arnett, FC., Deyo, RA., Felson, DT., Giannini, EH., Heyse, SP.,  
Hirsch, R., Hochberg, MC., Hunder, GG., Liang, MH., Pillemer, SR., Steen, VD., &  
Wolfe, F. (1998). Estimates of the prevalence of arthritis and selected  
musculoskeletal disorders in the United States. Arthritis Rheum, Vol.41, No.5, pp.  
778-799 
Leardini, G., Perbellini, A., Franceschini, M. & Mattara, L. (1988). Intra-articular injections of  
hyaluronic acid in the treatment of painful shoulder. Clin Ther, Vol.10, No.5, pp.  
521-526 
www.intechopen.com
  
Osteoarthritis – Diagnosis, Treatment and Surgery 
 
118 
Luciani, D., Cadossi, M., Tesei, F., Chiarello, E. & Giannini, S. (2008). Viscosupplementation  
for grade II osteoarthritis of the ankle : a prospective study at 18 months' follow –  
up. Chir Organi Mov, Dec, Vol.92, No.3, pp. 155-160 
Mader, R., Lavi, I. & Luboshitzky, R. (2005). Evaluation of the pituitary-adrenal axis function  
following single intraarticular injection of methylprednisolone. Arthritis Rheum,  
Vol.52, No.3, pp. 924-928 
Manfredini, D., Piccotti, F. & Guarda-Nardini, L. (2010). Hyaluronic acid in the treatment 
of  TMJ disorders: a systematic review of the literature. Cranio, Vol.28, No.3, pp. 
166-76 
Mei – Dan, O., Kish, B., Shabat, S., Masarawa, S., Shteren, A., Mann, G. & Nyska, M. (2010).  
Treatment of osteoarthritis of the ankle by intra – articular injections of hyaluronic  
acid: a prospective study. J Am Podiatr Med Assoc, Mar-Apr, Vol.100, No.2, pp. 93- 
100 
Merolla, G., Sperling, JW., Paladini, P. & Porcellini, G. (2011). Efficacy of Hylan G-F 20 
versus  6-methylprednisolone acetate in painful shoulder osteoarthritis: a 
retrospective  controlled trial. Musculoskelet Surg, May 13 
Migliore, A., Granata, M., Tormenta, S., Laganà, B., Piscitelli, P., Bizzi, E., Massafra, U.,  
Alimonti, A., Maggi, C., De Chiara, R., Iannessi, F., Sanfilippo, A., Sotera, R.,  
Scapato, P., Carducci, S., Persod, P., Denaro, S., Camminiti, M., Pagano, MG.,  
Bagnato, G. & Iolascon, G. (2011). Hip viscosupplementation under ultra-sound  
guidance riduces NSAID consumption in symptomatic hip osteoarthritis patients  
in a long follow-up. Data from Italian registry. Eur Rev Med Pharmacol Sci, Vol.15,  
No.1, pp. 25-34 
Migliore, A., Giovannangeli, F., Granata, M. & Laganà, B. (2010). Hylan g-f 20: review of its  
safety and efficacy in the management of joint pain in osteoarthritis. Clin Med  
Insights Arthritis Musculoskelet Disord, Vol.20, No.3, pp. 55-68 
Migliore, A., Tormenta, S., Massafra, U., Martin Martin, LS., Carloni, E., Padalino, C.,  
Alimonti, A. & Granata, M. (2006a).[18-month observational study on efficacy of  
intraarticular hyaluronic acid (Hylan G-F 20) injections under ultrasound guidance  
in hip osteoarthritis]. Reumatismo, Vol.58, No.1, pp. 39-49 
Migliore, A., Tormenta, S., Martin Martin, LS., Iannessi, F., Massafra, U., Carloni, E., Monno,  
D., Alimonti, A, Granata, M. (2006b). The symptomatic effects of intra-articular  
administration of hylan G-F 20 on osteoarthritis of the hip: clinical data of 6 months  
follow-up. Clin Rheumatol, Vol.25, No.3, pp. 389-393 
Migliore, A., Tormenta, S., Valente, C., Massafra, U., Martin Martin, LS., Carmenini, E.,  
Bernardini A & Alimonti, A. (2005). [Intra-articular treatment with Hylan G-F 20  
under ultrasound guidance in hip osteoarthritis. Clinical results after 12 months  
follow-up]. Reumatismo, Vol.57, No.1, pp. 36-43 
Migliore, A., Tormenta, S., Martin Martin, LS., Valente, C., Massafra, U., Latini, A. &  
Alimonti, A. (2004). [Safety profile of 185 ultrasound-guided intra-articular  
injections for treatment of rheumatic diseases of the hip]. Reumatismo, Vol.56, No.2,  
pp. 104-109 
www.intechopen.com
 Hyaluronic Acid in the Treatment of Osteoarthritis: What is New 
 
119 
Migliore, A., Martin, LS., Alimonti, A., Valente, C. & Tormenta, S. (2003). Efficacy and safety  
of viscosupplementation by ultrasound-guided intra-articular injection in  
osteoarthritis of the hip. Osteoarthritis Cartilage, Vol.11, No.4, pp. 305-306 
National Collaborating Centre for Chronic Conditions (UK). (2008). Osteoarthritis: National  
clinical guideline for care and management in adults. London: Royal College of  
Physicians (UK) 
O'Regan, M., Martini, I., Crescenzi, F., De Luca, C. & Lansing, M. (1994). Molecular  
mechanisms and genetics of hyaluronan biosynthesis. Int J Biol Macromol, Vol.16,  
No.6, pp. 283-286 
Pons, M., Alvarez, F., Solana, J., Viladot, R. & Varela, L. (2007). Sodium hyaluronate in the  
treatment of hallux rigidus. A single-blind, randomized study. Foot Ankle Int,  
Vol.28, No.1, pp. 38-42 
Pourbagher, MA., Ozalay, M. & Pourbagher, A. (2005). Accuracy and outcome of  
sonographically guided intra-articular sodium hyaluronate injections in patients  
with osteoarthritis of the hip. J Ultrasound Med, Vol.24, No.10, pp. 1391-1395 
Qvistgaard, E., Christensen, R., Torp-Pedersen, S. & Bliddal, H. (2006). Intra-articular  
treatment of hip osteoarthritis: a randomized trial of hyaluronic acid, corticosteroid, 
and isotonic saline. Osteoarthritis Cartilage, Vol.14, No.2, pp. 163-170 
Qvistgaard, E., Kristoffersen, H., Terslev, L., Danneskiold-Samsoe, B., Torp-Pedersen, S. &  
Bliddal, H. (2001). Guidance by ultrasound of intra-articular injections in the knee  
and hip joints. Osteoarthritis Cartilage, Vol.9, No.6, pp. 512-517 
Ravaud, P., Moulinier, L,, Giraudeau, B., Ayral, X., Guerin, C., Noel, E., Thomas, P., Fautrel,  
B., Mazieres, B. & Dougados, M. Effects of joint lavage and steroid injection in  
patients with osteoarthritis of the knee: results of a multicenter, randomized,  
controlled trial. Arthritis Rheum, Vol.42, No.3, pp. 475-482 
Roughead, EE., Ramsay, E., Pratt, N. & Gilbert, AL. (2008). NSAID use in individuals at risk  
of renal adverse events: an observational study to investigate trends in Australian  
veterans. Drug Saf, Vol.31, No.11, pp. 997-1003 
Roux, C., Fontas, E., Breuil, V., Brocq, O., Albert, C. & Euller-Ziegler, L. (2007). Injection of  
intra-articular sodium hyaluronidate (Sinovial) into the carpometacarpal joint of  
the thumb (CMC1) in osteoarthritis. A prospective evaluation of efficacy. Joint Bone  
Spine, Vol.74, No.4, pp. 368-372 
Rovetta, G. & Monteforte, P. (1998). Intraarticular injection of sodium hyaluronate plus  
steroid versus steroid in adhesive capsulitis of the shoulder. Int J Tissue React,  
Vol.20, No.4, pp. 125-130 
Salini, V., De Amicis, D., Abate, M., Natale, MA., Di Iorio, A. (2009). Ultrasound-guided  
hyaluronic acid injection in carpometacarpal osteoarthritis: short-term results. Int J  
Immunopathol Pharmacol, Vol.22, No.2, pp. 455-460 
Salk, RS., Chang, TJ., D'Costa, WF., Soomekh, DJ. & Grogan, KA. (2006). Sodium  
hyaluronate in the treatment of osteoarthritis of the ankle : a controlled,  
randomized, double – blind pilot study. J Bone Joint Surg Am, Feb, Vol.88, No.2, pp.  
295-302 
www.intechopen.com
  
Osteoarthritis – Diagnosis, Treatment and Surgery 
 
120 
Salk, R., Chang, T., D'Costa, W., Soomekh, D. & Grogan, K. (2005). Viscosupplementation  
(hyaluronans) in the treatment of ankle osteoarthritis. Clin Podiatr Med Surg, Oct,  
Vol.22, No.4, pp. 585-597 
Saltzman, CL., Salamon, ML., Blanchard, GM., Huff, T., Hayes, A., Buckwalter, JA. &  
Amendola, A. (2005). Epidemiology of ankle arthritis : report of a consecutive 
series of 639 patients from a tertiary orthopaedic center. Iowa Orthop J, Vol.25, pp. 
44-46 
Savage, R. (2005). Cyclo-oxygenase-2 inhibitors: when should they be used in the elderly?  
Drugs ageing, Vol.22, No.3, pp. 185-200 
Schumacher, HR., Meador, R., Sieck, M. & Mohammed, Y. (2004). Pilot Investigation of  
Hyaluronate Injections for First Metacarpal-Carpal (MC-C) Osteoarthritis. J Clin  
Rheumatol, Vol.10, No.2, pp. 59-62 
Silverstein, E., Leger, R. & Shea, KP. (2007). The use of intra-articular hylan G-F 20 in the  
treatment of symptomatic osteoarthritis of the shoulder: a preliminary study. Am J  
Sports Med, Vol.35, No.6, pp. 979-985 
Smalley, WE. & Griffin, MR. (1996). The risks and costs of upper gastrointestinal disease  
attributable to NSAIDs. Gastroenterol Clin North Am, Vol. 25, No.2, pp. 373-396 
Spacek, E., Poiraudeau, S., Fayad, F., Lefèvre-Colau, MM., Beaudreuil, J., Rannou, F.,  
Fermanian, J. & Revel, M. (2004). Disability induced by hand osteoarthritis: are  
patients with more symptoms at digits 2-5 interphalangeal joints different from  
those with more symptoms at the base of the thumb? Osteoarthritis Cartilage, Vol.12,  
No.5, pp. 366-373 
Srejic, U., Calvillo, O. & Kabakibou, K. (1999). Viscosupplementation: a new concept in the  
treatment of sacroiliac joint syndrome: a preliminary report of four cases. Reg  
Anesth Pain Med, Vol.24, No.1, pp. 84-88 
Stahl, S., Karsh-Zafrir, I., Ratzon, N. & Rosenberg, N. (2005). Comparison of intraarticular  
injection of depot corticosteroid and hyaluronic acid for treatment of degenerative  
trapeziometacarpal joints. J Clin Rheumatol, Vol.11, No.6, pp. 299-302 
Sturkenboom, MC., Romano, F., Simon, G., Correa-Leite, ML., Villa, M., Nicolosi, A.,  
Borgnolo, G., Bianchi-Porro, G. & Mannino, S. (2002). The iatrogenic costs  
of  NSAID therapy: a population study. Arthritis Rheum, Vol.47, No.2, pp. 132-
140 
Sun, SF., Chou, YJ., Hsu, CW., Hwang, CW., Hsu, PT., Wang, JL., Hsu, YW. & Chou, MC.  
(2006). Efficacy of intra – articular hyaluronic acid in patients with osteoarthritis of  
the ankle : a prospective study. Osteoarthritis & Cartilage, Sep, Vol.14, No.9, pp. 867- 
874 
Takahashi, K., Goomer, RS., Harwood, F., Kubo, T., Hirasawa, Y. & Amiel, D. (1999). The  
effects of hyaluronan on matrix metalloproteinase-3 (MMP-3), interleukin-
1beta(IL-1beta), and tissue inhibitor of metalloproteinase-1 (TIMP-1) gene 
expression during  the development of osteoarthritis. Osteoarthritis Cartilage, 
Vol.7, No.2, pp. 182-190 
Tamai, K., Mashitori, H., Ohno, W., Hamada, J., Sakai, H. & Saotome, K. (2004). Synovial  
response to intraarticular injections of hyaluronate in frozen shoulder: a  
www.intechopen.com
 Hyaluronic Acid in the Treatment of Osteoarthritis: What is New 
 
121 
quantitative assessment with dynamic magnetic resonance imaging. J Orthop Sci,  
Vol.9, No.3, pp. 230-234 
Tikiz, C., Unlu, Z., Sener, A., Efe, M. & Tuzun, C. (2005). Comparison of the efficacy of lower  
and higher molecular weight viscosupplementation in the treatment of hip  
osteoarthritis. Clin Rheumatol, Vol.24, No.3, pp. 244-250 
Vad, VB., Sakalkale, D., Sculco, TP. & Wickiewicz, TL. (2003). Role of hylan G-F 20 in  
treatment of osteoarthritis of the hip joint. Arch Phys Med Rehabil, Vol.84, No.8, pp.  
1224-1226 
Valiveti, M., Reginato, AJ. & Falasca, GF. (2006). Viscosupplementation for degenerative 
joint  disease of shoulder and ankle. Journal of Clinical Rheumatology, Vol.12, No.3, 
pp. 162- 163 
Van Brakel, RW. & Eygendaal, D. (2006). Intra-articular injection of hyaluronic acid is not  
effective for the treatment of post-traumatic osteoarthritis of the elbow. Arthroscopy,  
Vol.22, No.11, pp. 1199-1203 
Van den Bekerom, MP., Lamme, B., Sermon, A. & Mulier, M. (2008). What is the evidence for  
viscosupplementation in the treatment of patients with hip osteoarthritis?  Systematic 
review of the literature. Arch Orthop Trauma Surg, Vol.128, No.8, pp. 815- 823 
Van den Bekerom, MP., Mylle, G., Rys, B. & Mulier, M. (2006). Viscosupplementation in  
symptomatic severe hip osteoarthritis: a review of the literature and report on 60  
patients. Acta Orthop Belg, Vol. 72, No.5, pp. 560-568 
Waddell, DD. (2007). Viscosupplementation with hyaluronans for osteoarthritis of the knee:  
clinical efficacy and  economic implications. Drugs Aging, Vol.24, No.8, pp. 629-642 
Wang, W., Li, P., Zhang, YL., Yang, Y., Wang, FL. & Zhang, Y. (2002). [The clinical effects of  
percutaneous lumbar discectomy combined with sodium hyaluronate in the  
treatment of lumbar intervertebral disc herniation]. Zhongguo Xiu Fu Chong Jian Wai  
Ke Za Zhi, Vol.16, No.1, pp. 23-25 
Weiss, C. & Band, P. (1995). Musculoskeletal applications of hyaluronan and hylan. Potential  
uses in the foot and ankle. Clin Podiatr Med Surg, Vol.12, No.3, pp. 497-517 
Weitoft, T., Larsson, A., Saxne, T. & Ronnblom, L. (2005). Changes of cartilage and bone  
markers after intra-articular glucocorticoid treatment with and without  
postinjection rest in patients with rheumatoid arthritis. Ann Rheum Dis ,Vol.64,  
No.12, pp. 1750-1753 
Witteveen, AGH., Sierevelt, IN., Blankevoort, L., Kerkhoffs, GM. & van Dijk, CN. (2010).  
Intra – articular sodium hyaluronate injections in the osteoarthritic ankle joint :  
effects, safety and dose dependency. Foot Ankle Surg, Dec, Vol.16, No.4, pp. 159-163 
Witteveen, AGH., Giannini, S., Guido, G., Jerosch, J., Lohrer, H., Vannini, F., Donati, L.,  
Schulz, A., Scholl, J., Sierevelt, IN. & van Dijk, CN. (2008). A prospective multi –  
centre, open study of the safety and efficacy of hylan G-F 20 (Synvisc) in patients  
with symptomatic ankle (talo – crural) osteoarthritis. Foot and Ankle Surgery, Vol.14,  
No.3, pp. 145-152 
Woo, SB., Wong, TM., Chan, WL., Yen, CH., Wong, WC. & Mak, KL. (2010). Anatomic  
variations of neurovascular structures of the ankle in relation to arthroscopic  
portals: a cadaveric study of Chinese subjects. J Orthop Surg (Hong Kong), Apr,  
Vol.18, No.1, pp. 71-75 
www.intechopen.com
  
Osteoarthritis – Diagnosis, Treatment and Surgery 
 
122 
Zhang, Y. & Jordan, JM. (2010). Epidemiology of osteoarthritis. Clin Geriatr Med, Aug, 
Vol.26,  No.3, pp. 355-369 
Zwar, RB., Read, JW. & Noakes, JB. (2004). Sonographically guided glenohumeral joint  
injection. AJR Am J Roentgenol, Vol.183, No.1, pp. 48-50 
www.intechopen.com
Osteoarthritis - Diagnosis, Treatment and Surgery
Edited by Prof. Qian Chen
ISBN 978-953-51-0168-0
Hard cover, 404 pages
Publisher InTech
Published online 02, March, 2012
Published in print edition March, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Osteoarthritis is one of the most debilitating diseases affecting millions of people worldwide. However, there is
no FDA approved disease modifying drug specifically for OA. Surgery remains an effective last resort to
restore the function of the joints. As the aging populations increase worldwide, the number of OA patients
increases dramatically in recent years and is expected to increase in many years to come. This is a book that
summarizes recent advance in OA diagnosis, treatment, and surgery. It includes wide ranging topics from the
cutting edge gene therapy to alternative medicine. Such multifaceted approaches are necessary to develop
novel and effective therapy to cure OA in the future. In this book, different surgical methods are described to
restore the function of the joints. In addition, various treatment options are presented, mainly to reduce the
pain and enhance the life quality of the OA patients.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Michele Abate and Vincenzo Salini (2012). Hyaluronic Acid in the Treatment of Osteoarthritis: What is New,
Osteoarthritis - Diagnosis, Treatment and Surgery, Prof. Qian Chen (Ed.), ISBN: 978-953-51-0168-0, InTech,
Available from: http://www.intechopen.com/books/osteoarthritis-diagnosis-treatment-and-surgery/hyaluronic-
acid-in-the-treatment-of-osteoarthritis-what-is-new
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
